Aims: Platelets retain cytoplasmic messenger RNA and are capable of protein biosynthesis. Several diseases are known to impact the platelet transcriptome but the effect of non-valvular atrial fibrillation (NVAF) on platelet RNA transcript is essentially unknown. The aim of this study was to evaluate the impact of NVAF on platelet RNA transcript by measuring platelet genes expression in consecutive NVAF patients before and 3-4 months after pulmonary vein isolation (PVI) and compared to normal sinus rhythm controls (NSR).
| INTRODUCTION
Platelets are capable of synthesizing proteins in a regulated manner, dependent on platelet activation and integrin engagement whereby they retain megakaryocyte-derived RNA with the essential spliceosome necessary for translation. 1, 2 Correlation between transcript abundance and protein expression 3, 4 indicates that platelet messenger RNA (mRNA) alterations have both morphological and functional implications. Several diseases, including coronary artery disease, are known to impact the platelet transcriptome. [5] [6] [7] Non-valvular atrial fibrillation (NVAF) is associated with a fivefold increased risk of stroke and thromboembolism. 8 Thrombi arise in
| METHODS

| Patient recruitment
Recruitment methodology, exclusion criteria, and diagnostic protocol have been described previously. 10 col also included a follow-up visit 3-4 months after PVI to assess the recurrence of arrhythmia by careful interview, EKG, 24-hour Holter monitor, computed tomography or magnetic resonance imaging of the chest and heart was also repeated.
NSR control subjects consisted of individuals with no prior history of NVAF enrolled in parallel from the primary care clinic during annual medical examination or from a preoperative assessment for an elective minor outpatient procedure. The same exclusion criteria were applied to control subjects. This is a case-control study protocol of this was approved by the Institutional Review Boards of the Mayo Clinic and Foundation, and all research conduct was performed according to the ethical principles of the Declaration of Helsinki. All recruited individuals signed a consent form.
| Transesophageal echocardiogram
TEE was performed as previously described. 30 The left ventricular ejection fraction was visually estimated. The left atrial appendage emptying velocity was measured as previously described. 30 Spontaneous echocardiographic contrast was assessed and graded based on modified
Fatkin's criteria. 10, 31 Aortic atheroma was defined as "simple" when immobile and with thickness <4 mm or "severe" when exceeding 4 mm or with mobile components. 32 Left atrium volume index was calculated by the biplane area-length method 32 based on transthoracic echocardiogram assessment performed within 1 week of the TEE study. All echocardiographic images were evaluated by the study cardiologist (NA) who was blinded to clinical and laboratory data.
| Study definitions and event adjudication
The CHADS 2 score was assigned for each case and control subject. 33 The diagnosis of diabetes mellitus was made according to the criteria recommended by the American Diabetes Association. 34 Stroke and TIA were diagnosed based on the criteria proposed by the American Heart Association. 35 Atrial fibrillation was classified as "paroxysmal," or "persistent," or "permanent" in accordance with concurrent guidelines. 
| Peripheral blood platelets collection and RNA isolation
Each study participant had 40 mL ethylenediaminetetraacetic acid blood collected by venipuncture and centrifuged for 10 minutes at 150×g for platelet-rich plasma preparation. Leukocytes were then removed by Purecell ® PL High Efficiency Leukocyte Reduction Filter.
Purity of platelet preparation was assessed by flow cytometry using BD FACSCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ).
RNA was then extracted from platelets using the TRIzol ® Reagent. 10 All platelet preparations and handling were performed at room temperature within 60 minutes of blood collection.
| Platelet-specific genes expression assay
cDNA was generated from total RNA by first-strand cDNA synthe- (Table 1) , 13 were selected from a list of 50 platelet predominant genes. 3 Two additional, nonplatelet predominate genes (VWF gene encoding for von Willebrand factor and ADAMT gene encoding for ADAMTS 13 protease) were also included into this study. H2A histone family, member A gene (HIST1H2A) was used as the genetic indicator of platelet-specific tissue, as previously described.
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Target gene expression was normalized to β2 microglobulin gene-B2M (endogenous control) and presented as the cycle threshold (Ct) value in a kinetic PCR amplification curve. 36 To obtain ΔCt values, the data was analyzed using the BioMark Gene Expression Data Analysis software. All primers TaqMan assays were purchased through Applied Biosystems (Foster City, CA). All reactions were performed in triplicates to assure accuracy.
| Statistical analysis
Gene expression is presented as the ΔCt value in a kinetic PCR amplification curve after normalization to β2 microglobulin gene expression. 36 Consequently, the lower Ct value indicates the higher target 
| RESULTS
| Demographics
During the study period, 103 patients were recruited and blood samples collated properly. Details of patient recruitment can be found in the Supplemental file. During the same time period, 55 NSR controls were enrolled. Demographic variables and echocardiographic findings are available in the Supplement (Table S1 and Table S2 , respectively). 
T A B L E 1 List of genes with their symbols and a function of encoded proteins
| Platelet predominate genes expression
Expression of evaluated genes is presented in order of abundance ( Table S8 ).
Within the group of genes regulating VWF-ADAMTS13 function, expression of VWF gene was fourfold lower (two ΔCt) while genes encoding for integrin alfa2bbeta3 (ITGA2B) and ADAMTS13 (ADAMT) twofold lower in NVAF cases compared to NSR controls (see Table 2 ).
Moreover, expression of prostacyclin receptor gene (PTGIR) was fourfold lower and another two genes [SERCA3 gene (ATP2A3) and occludin (OCLN)] twofold lower in NVAF cases compared to NSR controls. Also F13A1 and ALOX12 genes had expression almost twofold lower in NVAF patients compared to NSR controls (see Table 2 ).
Expression of ADAMT gene was twofold lower in patients with persistent or permanent NVAF compared to those with paroxysmal arrhythmia (Table S3 ). NVAF patients with congestive heart failure had almost twofold lower expression of the VWF gene and prostacyclin receptor gene (Table S5) Table S3-Table S8 for complete data).
| Gene expression after catheter-based pulmonary vein isolation
Platelet predominate gene expression was measured before and 3-4 months after PVI (Table 3) . Over the time frame of this study, 65 patients were available for follow-up platelet measures. Baseline demographic, clinical, and echocardiographic variables did not differ between these 65 cases and the total cohort (data not shown).
Except three, all these patients had either symptomatic elimination or improvement NVAF after PVI. T A B L E 2 Platelet predominate genes expression presented as Δ CT in patients with non-valvular atrial fibrillation compared to individuals with normal sinus rhythm Following PVI, four genes had significantly increased expression (see Table 3 ). IGFALS expression increased 256-fold, ADAMT gene expression increased 16-fold, PF4 gene over twofold, and GP1BB gene expression nearly twofold after ablation. Expression of three genes encoding for cathepsin A (CTSA), GRB2-related adaptor protein (GRAP2), and integrin alfa2bbeta3 (ITGA2B) fell significantly after PVI but the decrease was lower than twofold compared to the value before ablation. The other eight genes showed no significant change in expression following PVI.
After PVI, nine patients had mild pulmonary vein stenosis noted during their repeated computed tomography or magnetic resonance imaging studies. This finding did not influence the expression of evaluated genes (data not shown). There was no difference in platelet transcript between these patients who came at the third month compared to the fourth month post-PVI (data not shown).
| DISCUSSION
This study shows that NVAF is associated with prominent changes in platelet transcript. In NVAF patients, expression of nearly all evaluated genes was lower compared to NSR controls. This observation appears to be of morphological and functional importance in the light of previously reported good association of platelet gene expression and proteomic. 3, 4 Twofold or higher difference in gene expression was consider to be of functional consequences by others. Nearly fourfold lower expression of VWF gene compared to NSR controls (particularly in those with heart failure) implies a reduction in platelet-derived VWF in NVAF patients which seems to contradict the results of previous studies reporting elevated plasma VWF in NVAF. 18, 30 However, constitutive plasma VWF is not determined by its synthesis and release from platelets but from endothelial cells. 19 When high molecular weight VWF multimers stored in platelets α-granules are released during stimulation, prothrombotic effect of these multimers is regulated by ADAMTS13 proteolytic activity. 20 Therefore, twofold lower expression of ADAMT gene in NVAF patients seems to imply significant reduction in local ADAMTS13 availability and shear which is coupled to platelet aggregation, integrin activation, and secretion. 24 The clinical importance of this positive feedback to platelet activation is evident by the widespread use of aspirin. Our finding of decreased ALOX12 expression in NVAF patients might represent another mechanism of relatively poor effectiveness of aspirin to prevent stroke in NVAF patients.
There are several potential limitations of this study that require reflection. First, a direct platelet proteomic analysis was not performed.
The association between platelet gene expression and the abundance of encoded protein, however, has been previously well documented. 3, 4 Second, a direct impact of the ablative procedure on the platelet transcript cannot be completely excluded. However, nine patients who developed mild pulmonary venous stenosis postablation implying a greater degree of injury related to PVI had no different platelet expression compared to those without scarification. Moreover, there was no difference in gene expression in those who had platelet transcript repeated 3 months compared to 4 months after ablation. Third, a selection bias cannot be excluded whereby only symptomatic NVAF patients undergoing catheter ablation of the pulmonary veins were recruited. Lastly, a number of controls and cases were relatively small, particularly after PVI. Further studies involving bigger number of participants are necessary.
In summary, platelet genes expression encoding for factors central to platelet functionality was found to be significantly lower in NVAF patients compared to NSR controls, in particular insulin-like growth factor binding protein acid labile subunit gene (16-fold lower), follow by genes encoding for prostacyclin receptor, and for von Willebrand factor (fourfold lower). Several demographic, echocardiographic variables, and clinical course of NVAF had impact on genes expression.
Platelet's ability to respond to the circulatory environment such as atrial fibrillation-related flow disturbances by altering transcript is remarkable and implies molecular "reprogramming" of platelets that should reciprocally influence the development of thrombotic complications of this arrhythmia.
